

1 **The effects of left vagus nerve block on postoperative nausea**  
2 **and vomiting in patients undergoing thoracic or abdominal**  
3 **laparoscopic surgery: A randomized controlled trial**

4

5 Chen Chen <sup>1</sup>, Zhongyu Yang <sup>1</sup>, Qi Zheng <sup>1</sup>, Yanghao Ren <sup>1</sup>, Tianyu Yang <sup>1</sup>, Xinyue Zhen  
6 <sup>1</sup>, Liang Ding <sup>1</sup>, Bingqian Fan <sup>1</sup>, Tianhai Wang <sup>1\*</sup>, Hongyan Dai <sup>2\*\*</sup>

7 <sup>1</sup> Department of Anesthesiology, Affiliated Cancer Hospital of Xinjiang Medical  
8 University, Urumqi, Xinjiang, China

9 <sup>2</sup> Basic Medical College Functional Center, Xinjiang Medical University, Urumqi,  
10 Xinjiang, China

11

12 \* Corresponding author. E-mail: wangth007@163.com (TW)

13 \*\* Corresponding author. E-mail: 277865891@qq.com (HD)

14

15

16

17

18

19

20

21

22

## 23 **Abstract**

24 **Purpose** To explore the influence of preoperative vagus nerve block (VNB) on  
25 postoperative nausea and vomiting (PONV) in patients undergoing thoracic or  
26 abdominal laparoscopic surgery.

27 **Methods** Patients were randomly divided into the VNB group (V group, n=60) and  
28 the control group (C group, n=60). The V group received left VNB before anesthesia  
29 induction, while the C group did not receive any intervention. The incidence and  
30 severity of PONV within one day after surgery were compared between the two groups  
31 to evaluate the effect of left VNB on PONV in patients.

32 **Results** The incidence of PONV in the V group (25%) was significantly lower than  
33 that in the C group (60%) ( $\chi^2 = 15.038, P < 0.001$ ). The incidences of mild and severe  
34 PONV in the V group were 16.67% and 8.33%, respectively, while those in the C group  
35 were 36.67% and 23.33%, respectively. The differences between the two groups were  
36 significant (mild:  $\chi^2 = 6.136, P = 0.013$ ; severe:  $\chi^2 = 5.065, P = 0.024$ ).

37 **Conclusion** Left VNB can reduce the incidence and severity of PONV caused by  
38 thoracic or abdominal laparoscopic surgery.

39 **Keywords** Laparoscopic surgery; Vagus nerve block; Postoperative nausea and  
40 vomiting.

41 **Trial registration** Trial was prospectively registered in the Chinese Clinical Trial  
42 Registry (number: ChiCTR2100044470).

43

44

## 45 **Introduction**

46 Postoperative nausea and vomiting (PONV) is a common complication following  
47 surgery. PONV not only prolongs the hospital stay of patients, increases hospitalization  
48 costs, and reduces patient satisfaction and quality of life, but also is one of the problems  
49 that plague anesthesiologists and surgeons [1-3].

50 Some studies have shown that the vagus nerve mediates the communication  
51 between the gut and brain, which is a key pathway in the occurrence of PONV [4-5].  
52 Scholar Xie *et al.* established a novel paradigm using a mouse model to study the  
53 "nausea-vomiting" response and found that vomiting depends on the "gut-to-brain  
54 axis," with the vagus nerve playing an important role [6]. Additionally, an observational  
55 cohort study by Li *et al.* indicated that vagus nerve resection during esophagectomy or  
56 gastrectomy reduced the incidence of PONV from 28.7% to 11.9% compared to  
57 procedures without vagus nerve resection [7]. Although this result suggests that  
58 blocking the vagus nerve that controls the gastrointestinal tract may inhibit the  
59 occurrence of PONV, the high technical demands on the surgeon, significant visceral  
60 trauma, and potential damage to surrounding normal tissue structures limit its clinical  
61 application. With the development of ultrasound technology, vagus nerve block (VNB)  
62 through the neck has made the injection process visualized, ensuring the safety of the  
63 procedure. Additionally, the nerve is surrounded by the carotid sheath, which limits the  
64 spread of local anesthetics. Therefore, the dose of local anesthetic required to block this  
65 nerve is relatively small, and the block duration is long, which has begun to be applied  
66 clinically [8-9].

67           Therefore, this study aims to explore the effect of left VNB on PONV in patients  
68   undergoing thoracic or abdominal laparoscopic surgery, to provide a new choice for the  
69   multimodal prevention and treatment strategy of PONV.

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

## 89 **Methods**

### 90 **Study design and ethics**

91 This study adheres to the Declaration of Helsinki, as revised in 2013 for human trials,  
92 and follows the applicable CONSORT guidelines. The study was registered on March  
93 18, 2021, in the Chinese Clinical Trial Registry (Registration No: ChiCTR210004447  
94 0), which is accessible at <https://www.chictr.org.cn/searchproj.html>. Additionally, on S  
95 eptember 20, 2021, the Ethics Committee of the Affiliated Cancer Hospital of Xinjian  
96 g Medical University (Chair: Professor Xiu Hua Zhang) granted ethical approval for th  
97 is study (Ethics No: K-2021053). The recruitment period of this study was from Septe  
98 mber 21, 2021 to October 30, 2022. Written informed consent was obtained from patie  
99 nts or their families before anesthesia and nerve block.

100

### 101 **Setting**

102 The trial will be conducted in the Anesthesia and Perioperative Medicine Center of  
103 the Affiliated Cancer Hospital of Xinjiang Medical University in Urumqi, Xinjiang,  
104 China.

105

### 106 **Patients**

107 A total of 130 patients scheduled for elective thoracic or abdominal laparoscopic  
108 surgery were included. A researcher (XZ) who was unaware of the group assignments  
109 learned about the patient's medical histories one day before surgery and signed the  
110 informed consent forms for anesthesia and nerve block with the families or patients.

111 The inclusion criteria were: (1) ASA class I-III; (2) aged 25-65 years; (3) no history of  
112 PONV; (4) patients undergoing elective thoracic or abdominal laparoscopic surgery.

113 The exclusion criteria were: (1) surgery duration less than 1 hour; (2) intraoperative  
114 blood loss over 800 ml; (3) allergy to medications used in the study; (4) neck or  
115 systemic infection; (5) neck deformity or large tumors; (6) hoarseness or deaf-muteness;  
116 (7) refusal to participate before nerve block.

117

## 118 **Randomization and blinding**

119 A researcher (CC) numbered the patients according to their order of surgery and used  
120 randomization software (<https://www.randomizer.org>) to randomly assign the patients  
121 to the VNB group (V group) or the control group (C group) in a 1:1 ratio. For each  
122 patient, a sealed opaque envelope was prepared. Before the surgery, a researcher (ZY)  
123 opened the envelope in the pre-anesthesia room outside the operating room and decided  
124 whether to perform VNB. Both groups of patients were handed over to an  
125 anesthesiologist (TY), who administered general anesthesia according to the same  
126 procedure. The anesthesiologists (excluding CC and ZY), surgeons, nurses, post-  
127 anesthetic care unit (PACU), and outcome assessors were all unaware of the group  
128 assignments.

129

## 130 **Perioperative management and intervention**

131 Patients did not receive preoperative medications on the day of surgery or the night  
132 before. Patients first entered the pre-anesthesia room outside the operating room, where

133 they underwent standard monitoring procedures. A central venous access was  
134 established, and peripheral arterial puncture and catheterization were performed to  
135 monitor the patient's mean arterial pressure (MAP). The patient was connected to a  
136 monitor to detect electrocardiogram (ECG), heart rate (HR), pulse oxygen saturation  
137 (SpO<sub>2</sub>), and other indicators.

138 The V group received ultrasound-guided left VNB in the pre-anesthesia room  
139 before anesthesia induction. The patient's head was turned to the right. The  
140 anesthesiologist (ZY) used a high-frequency linear ultrasound probe to perform short-  
141 axis scanning at the level of the fourth cervical vertebra transverse process. The internal  
142 jugular vein and carotid artery were found. The carotid artery, internal jugular vein, and  
143 vagus nerve are all surrounded by the carotid sheath. A round structure with stronger  
144 peripheral echoes and weaker central echoes can be detected posterior to the internal  
145 jugular vein and lateral to the carotid artery. This structure is the vagus nerve. The  
146 needle tip was inserted next to the vagus nerve in the carotid sheath. 0.5 ml of normal  
147 saline was injected to determine the needle tip position. After confirming that the needle  
148 tip position was correct, 3 ml of 0.5% ropivacaine was injected. During the injection  
149 process, attention should be paid to the direction of local anesthetic diffusion. Ideally,  
150 the diffusion should be towards the caudal end of the patient. If the drug diffuses  
151 towards the cephalic end, the upper part of the puncture site can be gently pressed to  
152 prevent the drug from diffusing towards the cephalic end to prevent excessive block  
153 level and affecting other nerves. A successful block was indicated by hoarseness within  
154 2-5 minutes. The C group did not undergo VNB, but all other procedures were the same

155 as those for the V group.

156 Fifteen minutes after the block was completed, the patient was pushed into the  
157 operating room. All patients were anesthetized and induced by the same  
158 anesthesiologist (TY). Anesthesia induction included midazolam (0.05 mg/kg),  
159 propofol (1.5 mg/kg), sufentanil (0.3 µg/kg), and rocuronium (0.6 mg/kg), followed by  
160 tracheal intubation. Mechanical ventilation was used for both groups, with a respiratory  
161 rate of 10-12 breaths/min, tidal volume of 6-8 ml/kg, and an I: E ratio of 1:2. Anesthesia  
162 was maintained with continuous infusions of propofol (2-4 mg/kg/h), remifentanil (0.5  
163 µg/kg/h), and rocuronium (0.5 mg/kg/h). Additional sufentanil (0.15 µg/kg) was  
164 administered at the end of surgery. All patients were given patient-controlled  
165 intravenous analgesia pumps after surgery. The drugs for patient-controlled analgesia  
166 were all 4 mg of butorphanol tartrate and 100 µg of sufentanil diluted to 100 ml with  
167 normal saline, with a flow rate of 2 ml/h.

168 After extubation, the patient was transferred to the PACU, where the same  
169 anesthesiologist (YR) was responsible for monitoring for at least 30 minutes until the  
170 modified Aldrete score reached more than 9 points as the discharge standard from the  
171 PACU. After the patient was sent back to the ward, the same clinician (QZ) was  
172 responsible. Whether in the PACU or the ward, no antiemetic drugs were given to the  
173 patient before the occurrence of postoperative nausea and vomiting. In addition,  
174 patients and their families were informed in advance to pay attention to the occurrence  
175 of nausea and vomiting within 24 hours after surgery, and the patient was arranged in a  
176 quiet ward to keep them away from factors that may induce nausea and vomiting.



## 177 **Observation indicators**

178 The collection of data was uniformly carried out by trained researchers (BF and LD).  
179 Preoperative general data of the two groups of patients were recorded: age, gender,  
180 weight, body mass index (BMI), American Society of Anesthesiologists (ASA)  
181 classification, and smoking history. Postoperative data recorded included the site of  
182 surgery, type of surgery, time of surgery, and the dosage of sufentanil used  
183 intraoperatively.

184 The primary outcomes were the incidence and severity of PONV on the first  
185 postoperative day. PONV is defined as the occurrence of nausea and vomiting within  
186 24 hours after surgery. Nausea is assessed based on the patient's subjective feeling of  
187 nausea or the urge to vomit. Both retching and vomiting are recorded as vomiting  
188 episodes. Retching is defined as the absence of gastric content expulsion, while any  
189 expulsion of gastric contents is recorded as vomiting. The severity is classified as mild  
190 (< 3 episodes/day) and severe ( $\geq 3$  episodes/day). Patients with only retching  
191 symptoms are recorded as having mild vomiting [10].

192 The secondary outcomes included: (1) the duration of hoarseness in the V group.  
193 (2) HR and MAP at T0 (10 minutes before nerve block), T1 (5 minutes before nerve  
194 block), T2 (during nerve block), T3 (5 minutes after nerve block), T4 (10 minutes after  
195 nerve block), and T5 (15 minutes after nerve block).

196

## 197 **Sample size calculation and statistical analysis**

198 We calculated the number of enrolled patients based on the incidence of PONV using

199 PASS2021 software. Firstly, we assessed that the incidence of PONV in 34 patients  
200 undergoing laparoscopic surgery was 50% (these 34 patients were not included in the  
201 subsequent trial). After patients received the intervention, the reduction in the incidence  
202 of PONV showed differences in different studies. The recorded differences were 26%  
203 [11], 28% [12], and 37.7% [13]. Therefore, We believe that a 30% reduction in the  
204 incidence of PONV is clinically significant. We hypothesized that after implementing  
205 left VNB, the incidence of PONV would be 20%, with an  $\alpha$  level of 0.05, power (1- $\beta$ )  
206 of 0.90, and an attrition rate of 20%, resulting in a required sample size of 65 patients  
207 per group.

208 In this study, IBM SPSS Statistics 26 software was used for data processing.  
209 Continuous variables that conformed to a normal distribution were expressed as mean  
210  $\pm$  standard deviation and compared between groups using the two independent samples  
211 *t*-test. Continuous variables that did not conform to a normal distribution were  
212 expressed as Median (Q1, Q3) and compared between groups using the Mann-Whitney  
213 U test. Categorical variables were described as number (percentages) and compared  
214 between groups using the chi-square test. A *P*-value less than 0.05 was considered  
215 statistically significant.

216

217

218

219

220

221 **Results**

222 **Patients' characteristic**

223 Between September 2021 and October 2022, a total of 130 patients were enrolled, of  
224 whom 2 were excluded based on exclusion criteria and 4 refused to participate. A total  
225 of 124 patients were recruited and randomly assigned to one of two groups, with 62  
226 patients in each group. One patient in the V group refused to accept the block before  
227 the procedure. Three patients were later excluded due to failure to complete follow-up.  
228 A total of 120 patients completed the study, including 60 in the V group and 60 in the  
229 C group (**Fig.1**). There were no significant differences in patient characteristics such as  
230 age, weight, BMI, gender, ASA classification, smoking status, site of surgery, type of  
231 surgery, time of surgery, and intraoperative sufentanil dosage between the two groups  
232 (**Table 1**).

233

234 **Fig.1. Trial flow chart.**

235

236 **Table 1** Demographic and surgical characters.

	V group (n=60)	C group (n=60)	P-value
Age, mean $\pm$ SD	55.15 $\pm$ 11.60	51.63 $\pm$ 12.64	0.115
Male gender, n (%)	21(35.00)	18(30.00)	0.559
Weight (kg), mean $\pm$ SD	62.40 $\pm$ 7.58	64.77 $\pm$ 9.51	0.134
BMI (kg/m <sup>2</sup> ), mean $\pm$ SD	23.48 $\pm$ 3.16	23.24 $\pm$ 2.97	0.659
Smoking history, n (%)	21(35.00)	16(26.66)	0.323
ASA class, n (%)			0.244
Class I	0(0.00)	2(3.33)	

Class II	45(75.00)	43(71.67)	
Class III	15(25.00)	15(25.00)	
Surgery site, n (%)			0.146
Right	22(36.67)	28(46.67)	
Left	35(58.33)	32(53.33)	
Mediastinum	3(5.00)	0(0.00)	
Surgery type, n (%)			0.166
Laparoscopic surgery	38(63.33)	45(75.00)	
Thoracoscopic surgery	22(36.67)	15(25.00)	
Surgery time (min), mean $\pm$ S	179.47 $\pm$ 52.64	186.80 $\pm$ 47.10	0.423
D			
Intraoperative sufentanil used (ug), median (Q1, Q3)	46.00(45.00, 46.00)	46.00(45.00, 46.00)	0.924
Postoperative hoarseness duration (hour), mean $\pm$ SD	8.3 $\pm$ 3.4	-	

237 Data are presented as mean  $\pm$  standard deviation, median (Q1, Q3), or number (percent-  
 238 tage).

239 Abbreviations: BMI, body mass index; ASA, American Society of Anesthesiologists. S  
 240 D, standard deviation.

241

## 242 Primary outcomes

243 The incidence of PONV in the V group (25%) was significantly lower than that in the  
 244 C group (60%) ( $\chi^2 = 15.038$ ,  $P < 0.001$ , [Table 2](#)). The incidences of mild and severe  
 245 PONV in the V group were 16.67% and 8.33%, respectively, while in the C group, they  
 246 were 36.67% and 23.33%, respectively. The differences between the two groups were  
 247 statistically significant (mild:  $\chi^2 = 6.136$ ,  $P = 0.013$ ; severe:  $\chi^2 = 5.065$ ,  $P = 0.024$ ,  
 248 [Table 2](#)).

249 **Table 2** Incidence and severity of PONV between the two groups.

	V group (n=60)	C group (n=60)	$\chi^2$	P-value
Incidence of PONV, n (%)	15(25.00)	36(60.00)	15.038	<0.001
Severity of PONV, n (%)				
Mild	10(16.67)	22(36.67)	6.136	0.013
Severe	5(8.33)	14(23.33)	5.065	0.024

250 Data are presented as numbers (percentages).

251 Abbreviations: PONV, postoperation nausea and vomiting.

252

## 253 **Secondary outcomes**

254 There were no significant differences in HR and MAP between the two groups at the  
255 same time points and between T1-T5 and T0 within each group (**Fig. 2**). The duration  
256 of hoarseness in the V group was  $8.3 \pm 3.4$  hours (**Table 1**).

257

258 **Fig.2. Comparison of HR and MAP at the same time points between the two groups**  
259 **and before and after nerve block within each group.** T0: 10 minutes before nerve  
260 block; T1: 5 minutes before nerve block; T2: during nerve block; T3: 5 minutes after  
261 nerve block; T4: 10 minutes after nerve block; T5: 15 minutes after nerve block. MAP:  
262 Mean arterial pressure; HR: Heart rate.

263

264

265

266

## 267 **Discussion**

268 In this study, we tracked the incidence of PONV within postoperative 24 hours. The  
269 results showed that the V group had a significantly lower incidence of PONV than the  
270 C group by 35% (**Table 2**). Additionally, comparing the severity of PONV between the  
271 two groups, the V group had fewer cases of mild and severe PONV, indicating that VNB  
272 can reduce the incidence and severity of PONV.

273 The vagus nerve, which is widely distributed in the gastrointestinal tract,  
274 transmits signals to the vomiting centers in the medulla's lateral reticular formation  
275 upon stimulation, enhancing the excitability of these centers [14]. These centers  
276 send instructions through the vagus nerve, sympathetic nerve, and phrenic nerve  
277 to the stomach and other related organs, triggering the vomiting response [15].  
278 Related studies suggest that the gut-vagus-brain reflex pathway, a typical emetic  
279 neural conduction pathway, plays a key role in PONV occurrence [6]. Studies have  
280 shown that gastrointestinal-related surgeries or traumas can cause the release of 5-  
281 HT<sub>3</sub> from enterochromaffin cells, leading to the activation of 5-HT<sub>3</sub> receptors at  
282 the vagus nerve afferent nerve endings, which in turn induces vagus nerve reflexes,  
283 nausea, and vomiting [16-17]. Similarly, anesthetics can enhance vagal afferent  
284 excitation by activating substance P and 5-HT<sub>3</sub> receptors [14]. Additionally,  
285 patients undergoing thoracic or abdominal laparoscopic surgery typically have  
286 higher intrathoracic and intra-abdominal pressures, and hypercapnia can activate  
287 related vagal reflexes, inducing nausea and vomiting [18-19]. The release of  
288 inflammatory mediators and cytokines caused by surgery mainly occurs within 24

289 hours after surgery [20-21], which suggests that the vagus nerve of patients may be in  
290 a state of high stimulation within 24 hours after surgery. We observed the duration of  
291 postoperative hoarseness in the V group (Table 1) and speculated that the average  
292 duration of left VNB was about 8 hours. Based on this, we hypothesize that left VNB  
293 can reduce the conduction of signals to the vomiting centers such as the dorsolateral  
294 margin of the lateral reticular formation of the medulla within 8 hours after surgery,  
295 thereby maintaining the excitability of the vomiting center at a lower level. The  
296 vomiting signals sent by the vomiting center to the efferent nerves are reduced,  
297 ultimately reducing the incidence and severity of PONV in patients. Therefore, we  
298 conclude that the left vagus nerve pathway in the neck may be one of the key factors in  
299 the occurrence of PONV. Blocking this neural conduction pathway can effectively  
300 reduce the incidence and severity of PONV.

301 In this study, we observed the effects of left VNB on the HR and MAP of patients  
302 at six-time points from T0 to T5. The results showed that there was no significant  
303 difference in HR and MAP before and after the block within the same group and at the  
304 same time points between the two groups (Fig. 2), indicating that left VNB has limited  
305 effects on HR and MAP. Considering the reasons: The heart is regulated by bilateral  
306 vagus nerves. The right vagus nerve dominates the function of the sinoatrial node and  
307 is more closely related to the atrium. The left vagus nerve is mainly related to the  
308 ventricle, and the vagus nerve innervation of the ventricle is not as dense as that of the  
309 atrium [22]. Therefore, left VNB generally does not have a significant impact on the  
310 heart.

311 This study has the following limitations: First, as a single-center study, the sample  
312 size is limited. Broader research and clinical validation are needed to confirm the  
313 universality of these findings. Second, this study only focused on the incidence and  
314 severity of PONV within the first day after surgery. No in-depth study was conducted  
315 on the situation for a longer time after surgery. In the future, the long-term effects of  
316 left VNB on PONV still need to be considered.

317 In summary, preoperative left VNB can prevent the incidence and severity of  
318 PONV caused by thoracic or abdominal surgery. Additionally, left VNB has no  
319 significant impact on hemodynamics (HR and MAP). Left VNB can be considered as  
320 a new option for preventing the occurrence of PONV.

321

322

323

324

325

326

327

328

329

330

331

332



333 **Author contributions** *Chen Chen*: data curation, formal analysis, method  
334 ology, project administration, software, validation, visualization, writing - original dra  
335 ft, writing - review & editing. *Zhongyu Yang*: performing VNB, methodology, writing  
336 original draft, review & editing. *Qi Zheng*: patient management, investigation, metho  
337 dology. *Yanghao Ren*: patient management, investigation, methodology. *Tianyu Yang*:  
338 patient management, investigation, methodology. *Xinyue Zhen*: investigation, metho  
339 dology. *Liang Ding*: data collection. *Bingqian Fan*: data collection. *Tianhai Wang*: c  
340 onceptualization, formal analysis, funding acquisition, methodology, project administr  
341 ation, resources, supervision, validation, writing - review & editing; *Hongyan Dai*: co  
342 nceptualization, formal analysis, methodology, project administration, resources, softw  
343 are, supervision, validation.

344 **Acknowledgments** None.

345 **Disclosures** The authors report no conflicts of interest.

346 **Funding statement** None.

347

348

349

350

351

352

353

354

## 355 **References**

- 356 [1] Gress K, Urits I, Viswanath O, *et al.* Clinical and economic burden of postoperati  
357 ve nausea and vomiting: Analysis of existing cost data [J]. *Best Pract Res Clin An*  
358 *aesthesiol.* 2020 Dec;34(4):681-686.
- 359 [2] Huh H. Postoperative nausea and vomiting in spinal anesthesia [J]. *Korean J Anes*  
360 *thesiol.* 2023 Apr;76(2):87-88.
- 361 [3] Cho YJ, Choi GJ, Ahn EJ, *et al.* Pharmacologic interventions for postoperative na  
362 usea and vomiting after thyroidectomy: a systematic review and network meta-an  
363 alysis [J]. *PLoS One.* 2021;16:e0243865.
- 364 [4] Karakan T, Ozkul C, Küpeli Akkol E, *et al.* Gut-Brain-Microbiota Axis: Antibioti  
365 cs and Functional Gastrointestinal Disorders [J]. *Nutrients.* 2021 Jan 27;13(2):38  
366 9.
- 367 [5] Browning KN, Carson KE. Central Neurocircuits Regulating Food Intake in Resp  
368 onse to Gut Inputs-Preclinical Evidence [J]. *Nutrients.* 2021 Mar 11;13(3):908.
- 369 [6] Xie Z, Zhang X, Zhao M, *et al.* The gut-to-brain axis for toxin-induced defensive  
370 responses [J]. *Cell.* 2022 Nov 10;185(23):4298-4316.e21.
- 371 [7] Li N, Liu L, Sun M, *et al.* Predominant role of gut-vagus-brain neuronal pathway  
372 in postoperative nausea and vomiting: evidence from an observational cohort stud  
373 y [J]. *BMC Anesthesiol.* 2021 Sep 29;21(1):234.
- 374 [8] Gong WY, Zhang JY, Wang AZ, *et al.* The combination of paravertebral block and  
375 cervical vagus nerve block applied alone for anaesthesia of open appendectomy d  
376 uring COVID-19 [J]. *Anaesth Crit Care Pain Med.* 2022 Aug;41(4):101091.

- 377 [9] Gong WY, Yue XF, Cheng C, *et al.* The application of cervical vagus nerve block  
378 in the awake video-assisted thoracic surgery for bullectomy [J]. *Anaesth Crit Care*  
379 *Pain Med.* 2021 Apr;40(2):100823.
- 380 [10] Manahan MA, Basdag B, Kalmar CL, *et al.* Risk of severe and refractory postope  
381 rative nausea and vomiting in patients undergoing deep flap breast reconstruction  
382 [J]. *Microsurgery.* 2014 Feb;34(2): 112-21.
- 383 [11] Ham SY, Shim YH, Kim EH, *et al.* Aprepitant for antiemesis after laparoscopic g  
384ynaecological surgery: A randomised controlled trial [J]. *Eur J Anaesthesiol.* 2016  
385 Feb;33(2):90-5.
- 386 [12] Jung WS, Kim YB, Park HY, *et al.* Oral administration of aprepitant to prevent po  
387 stoperative nausea in highly susceptible patients after gynecological laparoscopy  
388 [J]. *J Anesth.* 2013 Jun;27(3):396-401.
- 389 [13] de Morais LC, Sousa AM, Flora GF, *et al.* Aprepitant as a fourth antiemetic proph  
390 ylactic strategy in high-risk patients: a double-blind, randomized trial [J]. *Acta An*  
391 *aesthesiol Scand.* 2018 Apr;62(4):483-492.
- 392 [14] Zhong W, Shahbaz O, Teskey G, *et al.* Mechanisms of Nausea and Vomiting: Cur  
393 rent Knowledge and Recent Advances in Intracellular Emetic Signaling Systems  
394 [J]. *Int J Mol Sci.* 2021 May 28;22(11):5797.
- 395 [15] Browning KN, Carson KE. Central Neurocircuits Regulating Food Intake in Resp  
396 onse to Gut Inputs-Preclinical Evidence [J]. *Nutrients.* 2021 Mar 11;13(3):908.
- 397 [16] Denholm, L, Gallagher, G. Physiology and pharmacology of nausea and vomiting  
398 [J]. *Anaesthesia & Intensive Care Medicine.* 2021 Oct;22(10):663-666.

- 399 [17] Browning KN. Role of central vagal 5-HT<sub>3</sub> receptors in gastrointestinal physiolo  
400 gy and pathophysiology [J]. *Front Neurosci*. 2015 Oct 29;9:413.
- 401 [18] Besir A, Tugcugil E. Comparison of different end-tidal carbon dioxide levels in pr  
402 eventing postoperative nausea and vomiting in gynaecological patients undergoin  
403 g laparoscopic surgery [J]. *J Obstet Gynaecol*. 2021 Jul;41(5):755-762.
- 404 [19] Fujimoto D, Egi M, Makino S, *et al*. The association of intraoperative end-tidal ca  
405 rbon dioxide with the risk of postoperative nausea and vomiting [J]. *J Anesth*. 202  
406 0 Apr;34(2):195-201.
- 407 [20] Bain CR, Myles PS, Corcoran T, *et al*. Postoperative systemic inflammatory dysre  
408 gulation and corticosteroids: a narrative review [J]. *Anaesthesia*. 2023 Mar;78(3):  
409 356-370.
- 410 [21] Hirsch J, Vacas S, Terrando N, *et al*. Perioperative cerebrospinal fluid and plasma  
411 inflammatory markers after orthopedic surgery [J]. *J Neuroinflammation*. 2016 A  
412 ug 30;13(1):211.
- 413 [22] Ramani R. Vagus nerve stimulation therapy for seizures [J]. *J Neurosurg Anesthes*  
414 iol. 2008 Jan;20(1):29-35.

# CONSORT 2010 Flow Diagram

medRxiv preprint doi: <https://doi.org/10.1101/2024.11.08.24316971>; this version posted November 8, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

## Enrollment

Assessed for eligibility (n=130)

Excluded (n=6)

- ◆ Not meeting inclusion criteria (n=2)
- ◆ Declined to participate (n=4)

Randomized (n=124)

## Allocation

Allocated to the V group (n=62)

- ◆ Received allocated intervention (n=61)
- ◆ Did not receive allocated intervention (n=1)

Allocated to the C group (n=62)

- ◆ Received allocated intervention (n=62)
- ◆ Did not receive allocated intervention (n=0)

## Follow-Up

Lost to follow-up (n=1)

Discontinued intervention (n=0)

Lost to follow-up (n=2)

Discontinued intervention (n=0)

## Analysis


Analysed (n=60)

- ◆ Excluded from analysis (n=0)

Analysed (n=60)

- ◆ Excluded from analysis (n=0)

Figure 1



Indicators	Group	T0	T1	T2	T3	T4	T5
HR	V group (n=60)	74.63 ± 10.01	73.70 ± 10.16	72.78 ± 10.04	75.65 ± 9.42	74.47 ± 10.01	74.88 ± 10.38
	C group (n=60)	73.50 ± 10.21	74.77 ± 10.90	74.25 ± 11.06	74.52 ± 10.63	75.38 ± 10.34	74.35 ± 10.93
	<i>P</i> -value	0.540	0.580	0.449	0.538	0.623	0.785
MAP	V group (n=60)	92.72 ± 9.05	92.99 ± 8.69	92.40 ± 8.61	92.72 ± 8.45	92.19 ± 8.87	92.58 ± 8.00
	C group (n=60)	92.97 ± 6.35	94.20 ± 7.37	94.04 ± 7.49	93.53 ± 7.79	92.76 ± 8.19	92.23 ± 7.63
	<i>P</i> -value	0.861	0.414	0.266	0.588	0.717	0.807

Figure 2